))
Joyce O’Shaughnessy MD | Pembrolizumab + KEYNOTE-522 Trial, Trastuzumab Deruxtecan, CDK 4/6 Inhibitors & MonarchE Trial Data
Архівні серії ("Канал неактуальний" status)
When?
This feed was archived on October 16, 2023 13:30 (
Why? Канал неактуальний status. Нашим серверам не вдалося отримати доступ до каналу подкасту протягом тривалого періоду часу.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 327387457 series 3302009
Вміст надано PrecisCa. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією PrecisCa або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
On this episode, PrecisCa speaks with Dr. Joyce O'Shaughnessy, a medical oncologist and the Director of Breast Cancer Research Program at Baylor University Medical Center in Dallas, Texas. Dr. O'Shaughnessy sits down with us to answer the following questions:
…
continue reading
- Which breast cancer patients are eligible for preoperative pembrolizumab in the curative setting based on the KEYNOTE-522 trial? What about adjuvant pembrolizumab?
- How is trastuzumab deruxtecan optimally utilized for HER2+ metastatic breast cancer?
- Which CDK 4/6 inhibitor is recommended for treatment of HR+ HER2- metastatic breast cancer based on available survival data?
- Can you discuss the data from the MonarchE Trial that led to FDA approval of abemaciclib in October 2021?
Dr. O’Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995. Dr. O’Shaughnessy is a member of American Association for Cancer Research; American Society of Clinical Oncology; American Medical Women’s Association; American Medical Association; American College of Physicians; and Women in Cancer Research. Dr. O’Shaughnessy is an Associate Editor, Clinical Breast Cancer Journal; founder, The School of Breast Oncology.
Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content.18 епізодів
Поширити
